Half-year report · HY
7071.TEDINET S100Y3ZE
Period2025-10-01 → 2026-03-31
Filed2026-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥25.6bn | 2025-10-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥49.2bn | 2024-10-01 → 2025-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.8bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Operating income | ¥2.8bn | 2025-10-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥3.7bn | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.8bn | 2025-10-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.3bn | 2024-10-01 → 2025-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.8bn | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-10-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.8bn | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2025-10-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2024-10-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2025-10-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥83.9bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥83.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥82.7bn | at 2025-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥46.0bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥47.8bn | at 2025-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥37.9bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥36.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥35.2bn | at 2025-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.2bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.8bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.9bn | at 2024-09-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.8bn | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.0bn | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.2bn | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.4bn | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.9bn | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.2bn | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥6.4bn | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥6.5bn | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.41 | 2025-10-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.52 | 2024-10-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.55 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥19.41 | 2025-10-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.51 | 2024-10-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.55 | 2024-10-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 45.2% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.0% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 23
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-10-01 → 2026-03-31 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-10-01 → 2026-03-31 | −¥2m |
| Reconciling Itemsreconciling | segment profit | 2025-10-01 → 2026-03-31 | ¥0 |
| Comprehensive Medical Supportreportable segment | revenue | 2025-10-01 → 2026-03-31 | ¥569m |
| Comprehensive Medical Supportreportable segment | revenue external | 2025-10-01 → 2026-03-31 | ¥567m |
| Comprehensive Medical Supportreportable segment | revenue intersegment | 2025-10-01 → 2026-03-31 | ¥2m |
| Comprehensive Medical Supportreportable segment | segment profit | 2025-10-01 → 2026-03-31 | ¥324m |
| Ishinkanreportable segment | revenue | 2025-10-01 → 2026-03-31 | ¥25.0bn |
| Ishinkanreportable segment | revenue external | 2025-10-01 → 2026-03-31 | ¥25.0bn |
| Ishinkanreportable segment | segment profit | 2025-10-01 → 2026-03-31 | ¥2.5bn |
| —segment total | revenue | 2025-10-01 → 2026-03-31 | ¥25.6bn |
| —segment total | revenue external | 2025-10-01 → 2026-03-31 | ¥25.6bn |
| —segment total | revenue intersegment | 2025-10-01 → 2026-03-31 | ¥2m |
| —segment total | segment profit | 2025-10-01 → 2026-03-31 | ¥2.8bn |
| Comprehensive Medical Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥228m |
| Comprehensive Medical Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥228m |
| Comprehensive Medical Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥68m |
| Ishinkanreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥23.6bn |
| Ishinkanreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥23.6bn |
| Ishinkanreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥3.7bn |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥23.8bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥23.8bn |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥3.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)PwC Japan有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)新 田 將 貴 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)八 木 正 憲 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1InterimDuration | 23820000000 | JPY |
| Net sales (5-year summary) | InterimDuration | 25600000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 49174000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1InterimDuration | 3812000000 | JPY |
| Ordinary income loss (5-year summary) | InterimDuration | 2789000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 6343000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1InterimDuration | 2688000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | InterimDuration | 1896000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 3660000000 | JPY |
| Comprehensive income (5-year summary) | Prior1InterimDuration | 2688000000 | JPY |
| Comprehensive income (5-year summary) | InterimDuration | 1898000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 3647000000 | JPY |
| Net assets (5-year summary) | Prior1InterimInstant | 35157000000 | JPY |
| Net assets (5-year summary) | InterimInstant | 37938000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 36132000000 | JPY |
| Total assets (5-year summary) | Prior1InterimInstant | 82678000000 | JPY |
| Total assets (5-year summary) | InterimInstant | 83923000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 83947000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1InterimDuration | 27.55 | |
| Basic earnings loss per share (5-year summary) | InterimDuration | 19.41 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 37.52 | |
| Diluted earnings per share (5-year summary) | Prior1InterimDuration | 27.55 | |
| Diluted earnings per share (5-year summary) | InterimDuration | 19.41 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 37.51 | |
| Equity to asset ratio (5-year summary) | Prior1InterimInstant | 0.425 | |
| Equity to asset ratio (5-year summary) | InterimInstant | 0.452 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.430 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1InterimDuration | 3281000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | InterimDuration | 3766000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 6025000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1InterimDuration | -6870000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | InterimDuration | -3228000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -10427000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1InterimDuration | 6534000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | InterimDuration | -2160000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 6365000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1InterimInstant | 11814000000 | JPY |
| Cash and cash equivalents (5-year summary) | InterimInstant | 9210000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 10833000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 98112000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 98112000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 98112000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 98112000 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 51662000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.5266 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |